Navidea Biopharmaceuticals Inc. (AMEX:NAVB) saw a downside of -9.49% to $0.08 after subtracting -$0.01on Wednesday. The 5-day average trading volume is 2,481,556 shares of the company’s common stock. It has gained $0.0940 in the past week and touched a new high 2 times within the past 5 days. An average of 3,570,699 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 7,909,368.
NAVB’s 1-month performance is -9.69% or -$0.0260 on its low of $0.0626 reached on 08/07/23. The company’s shares have touched a 52-week low of $0.06 and high of $0.43, with the stock’s rally to the 52-week high happening on 02/08/23. YTD, NAVB has lost -61.38% or -$0.1289 and has reached a new high 4 times. However, the current price is down -81.27% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
NAVB stock has a beta of 1.48. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 998.03.
Navidea Biopharmaceuticals Inc.’s quick ratio for the period ended September 29 was 0.80, with the current ratio over the same period at 0.80. The trailing 12-month EBITDA margin is -21091.77%. The firm’s gross profit as reported stood at -$0.12 million against revenue of $66000.0.
Earnings Surprise
For the quarterly period ending September 29 this year, Net income grew 151.55% to $5.82 million, while revenue of -$1.48 million was 125.43% off the previous quarter. Analysts expected NAVB to announce -$0.11 per share in earnings in its latest quarter, but it posted -$0.08, representing a 27.30% surprise. EBITDA for the quarter stood at more than -$2.29 million. NAVB stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 9.01 million, with total debt at $1.34 million. Shareholders hold equity totaling $99.83 million.
Let’s look briefly at Navidea Biopharmaceuticals Inc. (NAVB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 47.54% to suggest the stock is trending Neutral, with historical volatility in this time period at 179.59%.
The stock’s 5-day moving average is $0.0857, reflecting a -15.52% or -$0.0149 change from its current price. NAVB is currently trading -9.59% above its 20-day SMA, -74.66% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -6.03% and SMA200 by-65.84%.
Stochastic %K and %D was 48.27% and 50.48% and the average true range (ATR) pointed at 0.0117. The RSI (14) points at 46.63%, while the 14-day stochastic is at 40.04% with the period’s ATR at 0.0119. The stock’s 9-day MACD Oscillator is pointing at 0.0025 and 0.0065 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Navidea Biopharmaceuticals Inc. (AMEX: NAVB), Aegis Capital reiterated its a Hold rating for the company but lifted their price target by $3 to $2. Analysts offering their rating for NAVB stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate NAVB as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is NAVB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $8.00 and a high of $8.00, with their median price target at $8.00. Looking at these predictions, the average price target given by analysts is for Navidea Biopharmaceuticals Inc. (NAVB) stock is $8.00.
